title: What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
abstract: In the past decade, the treatment of chronic myeloid leukemia (CML) has undergone a drastic evolution. The discovery and success of imatinib and second-generation tyrosine kinase inhibitors have substantially increased the outcome for CML patients. The next step in medical and scientific research is to better understand the malignancy so as to eventually find a cure to eliminate all leukemic cells from patients. One of the key issues is about the resistance of the leukemic stem cells to tyrosine kinase inhibitors. Here, we briefly describe our current studies on CML resistance, and leukemic stem cell modeling and characterization.
authors.affiliation: Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Lewis
authors.affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, Glasgow City Counsil, UK.
authors.forename: Mhairi
authors.initials: M
authors.lastname: Copland
authors.affiliation: Department of Experimental, Diagnostic and Specialty Medicine, Haematology/Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Emilia-Romagna, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Soverini
authors.affiliation: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Vienna, Austria.
authors.forename: Irina
authors.initials: I
authors.lastname: Sadovnik
authors.affiliation: Biothérapie de Maladies Génétiques et Cancer, INSERM U1035, Université de Bordeaux, Bordeaux, Gironde, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Bedel
authors.affiliation: CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), F-92265, Fontenay-aux-Roses, Île de France, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Prost
authors.affiliation: Department of Medical Oncology, Bergonié Institute, Bordeaux, Gironde, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.affiliation: Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Mahon
mesh_terms: D049674:History, 21st Century; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors
keywords: chronic myeloid leukemia; leukemic stem cells; resistance to treatment; tyrosine kinase inhibitors